✉️Autotelic Bio NEWSLETTER. April 2023 ✉️
2023-04-28
Autotelic Bio and Yungjin Pharm. Entered Co-Development and Technical Implementation of Hypertension and Diabetic Combination Drug
2023-03-14
✉️Autotelic Bio NEWSLETTER. February 2023 ✉️
2023-02-28
✉️Autotelic Bio NEWSLETTER. December 2022 ✉️
2022-12-30
Autotelic Bio's ATB-610, a Selective ALK5 Inhibitor with Inhalation Therapy for IPF Treatment, was Selected as a Research Project by KDDF
2022-11-25
Autotelic Bio to Initiate Phase 3 Clinical Trial for ATB-101, the World's 1st FDC for Hypertension and Diabetes
2022-07-04
